Abstract Purpose Pharmacist management of care for patients with inflammatory bowel disease (IBD) encompasses therapy education and optimization, monitoring, adherence support, and immunosuppression safety processes and thereby holds substantial promise for improving patient outcomes. However, the absence of a structured set of quality measures often results in fragmented efforts among clinic-based pharmacists, specialty pharmacy pharmacists, and managed care pharmacists. To address this shortcoming, we used an established modified Delphi process to develop and prioritize pharmacist-driven quality measures for the care of patients with IBD. Methods This multisite project was conducted at Mayo Clinic in Minnesota, Arizona, and Florida from October 30, 2023, through February 6, 2024. Stakeholders included IBD physicians, clinic-based pharmacists in medication management services, specialty pharmacy pharmacists, managed care pharmacists, and pharmacy leadership. An environmental scan identified existing quality measures, and a subsequent 3-round modified Delphi process was used to rate the quality measures for importance, feasibility, and validity before final ranking and consensus review. Results Thirty-one potential quality measures were identified. We prioritized 10 quality measures that emphasized adherence, safety screening, and timeliness of treatment initiation. These consensus-derived quality measures provided a foundation for systemwide performance tracking and quality improvement in pharmacist-led IBD care. Conclusion Prioritized quality measures were successfully identified to create a consistent, systemwide quality framework for pharmacist-led IBD care. Implementation of shared documentation standards and electronic health record–embedded tools are critical next steps to streamline efforts and monitor their effects on the quality of care for patients with IBD.
A Comparison of Two Strategies for Converting to Adalimumab Biosimilarsa
Abstract Purpose We retrospectively compared 2 strategies for adalimumab biosimilar conversion at an academic medical center to better understand the effects of each strategy. Methods The formulary for our institution is managed by physician- and pharmacist-led task forces, in collaboration with our specialty pharmacy and pharmacy benefit manager. We implemented 2 phased strategies to increase adalimumab biosimilar utilization. First, we added preferred biosimilars to the formulary at parity to reference product and relied on prescribers to promote conversion. Second, we added an interchangeable biosimilar and removed reference product from the formulary while leveraging specialty pharmacy workflows for prescription conversions, streamlined facility inventory, and minimized dependence on prescriber workflows. For both strategies, we evaluated prescribing trends, dispensing data, and pharmaceutical spend for all medical center patients, specialty pharmacy patients, and patients with the top 3 specialty pharmacy payers. Results During phase 1 (quarter [Q] 2 of 2023 [2Q23] to 1Q24), reference product dispensing remained largely unchanged (<5% reduction). Phase 2 (2Q24 to 2Q25) resulted in a significant reduction in specialty pharmacy dispenses of reference product, from 95.7% to 19.0%. This phase also resulted in a 76.0% reduction in medical center adalimumab/biosimilar spend. At the end of phase 2, biosimilar accounted for 42.6% of all medical center patient prescriptions. Total dispensed units of reference product/biosimilar were modestly decreased (6%) during phase 2. Conclusion Formulary and clinical support for adalimumab biosimilar alone did not promote use over the reference product, but rapid and substantial biosimilar uptake was achieved after operational barriers were addressed.